NumerixS Investment Technologies’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

NumerixS Investment Technologies’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-200	Closed	-$31K	–	928
2020 Q2	$31K	Buy	+200	New	+$30.4K	0.01%	894
2019 Q2	–	Sell	-2,200	Closed	-$186K	–	1414
2019 Q1	$186K	Buy	+2,200	New	+$183K	0.02%	689
2016 Q3	–	Sell	-300	Closed	-$6K	–	1352
2016 Q2	$6K	Buy	+300	New	+$5.83K	﹤0.01%	1082

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

NumerixS Investment Technologies's RETA Position: Q3 2020 in Review

NumerixS Investment Technologies sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2020, closing a stake of 200 shares — an estimated $31K sold.

NumerixS Investment Technologies first reported a position in RETA in Q2 2016 and held it in 3 quarters. The position peaked at $186K in Q1 2019. 186 funds tracked by Wall St. Rank hold RETA as of Q3 2020.

NumerixS Investment Technologies reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2020 after selling out during the quarter.
NumerixS Investment Technologies sold 200 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2020, an estimated $31K.
NumerixS Investment Technologies first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and held it in 3 quarters.
NumerixS Investment Technologies's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $186K in Q1 2019.
186 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2020.

Based on NumerixS Investment Technologies's 13F filing for Q3 2020.